All In Biotech

NDA 019569 · Mission Pharma

Thiola

Tiopronin · Oral · Reducing and Complexing Thiol

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jun 28, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1988

Aug 11, 1988

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

0 Phase 3, 0 recruiting

FAERS reports

1,772

332 serious, 59 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 27, 2026.

THIOLA is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone. --------------------------------------------INDICATIONS AND USAGE----------------------------------------- THIOLA is a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone. (1)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 11, 1988 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • THIOLA · TIOPRONIN 100MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tiopronin" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective502
  • drug dose omission257
  • nausea150
  • pain108
  • pyrexia83
  • rash83
  • nephrolithiasis82
  • fatigue71
  • arthralgia70
  • vomiting67
  • pruritus64
  • diarrhoea58

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20056
20061
20074
20085
20092
20108
201136
201237
20138
20143
2015158
2016329
2017592
2018279
201946
202021
202119
202246
202328
202444
202565
202632

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Thiola (Tiopronin)

2024 spending

$3.6M

Beneficiaries

50

521 claims

Per beneficiary

$72,743

$28.60 per unit

View as table
YearSpending
2020$5,902,003
2021$5,478,571
2022$4,164,266
2023$3,477,681
2024$3,637,147

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 43 on PubMed

Sponsor: Mission Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.